Aims and objectives of this session
The mainstay of OAB treatment is medical management. Since decades a search is going on to find the ideal drug for OAB treatment. A drug should be effective, should not have many and severe side events and should be safe. So far the ideal drug has not been found. This implies that other options like the combination of drugs, also qualify for treatment. This session explores the feasibility of drug combination for OAB.

10:30 - 10:45  
**OAB drugs: What's new from the bench?**  
M.C. Michel, Mainz (DE)

10:45 - 11:00  
**Role of drug combination therapy for OAB management**  
F. Van Der Aa, Leuven (BE)

11:00 - 11:00  
**Case presentation faculty:**  
S. Charalampous, Limassol (CY)  
E. Finazzi Agrò, Rome (IT)  
T.A.T. Marcelissen, Maastricht (NL)  
M.I.A. Wyndaele, Utrecht (NL)

11:00 - 11:15  
**Case 1**  
Woman, 50 years old, with mixed incontinence an predominant OAB

11:00 - 11:03  
**Case presentation**

11:03 - 11:06  
Preferred anticholinergic  
S. Charalampous, Limassol (CY)

11:06 - 11:09  
Preferred mirabegron  
E. Finazzi Agrò, Rome (IT)

11:09 - 11:12  
No drugs - prefers PTNS  
T.A.T. Marcelissen, Maastricht (NL)

11:12 - 11:15  
Something else  
M.I.A. Wyndaele, Utrecht (NL)

11:15 - 11:30  
**Case 2**  
Man, 50 years old, with OAB after Benign Prostatic Obstruction (BPO) relief

11:15 - 11:18  
**Case presentation**
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 11:18 - 11:21 | Prefers an anticholinergic  
M.I.A. Wyndaele, Utrecht (NL) |
| 11:21 - 11:24 | Prefers mirabegron  
T.A.T. Marcelissen, Maastricht (NL) |
| 11:24 - 11:27 | No drugs - prefers PTNS  
E. Finazzi Agrò, Rome (IT) |
| 11:27 - 11:30 | Something else  
S. Charalampous, Limassol (CY) |
| 11:30 - 11:45 | Case 3  
Man, 60 years old, Parkinson disease, presenting with OAB |
| 11:33 - 11:45 | Case presentation |
| 11:36 - 11:39 | Prefers an anticholinergic  
E. Finazzi Agrò, Rome (IT) |
| 11:39 - 11:42 | Prefers mirabegron  
M.I.A. Wyndaele, Utrecht (NL) |
| 11:42 - 11:45 | No drugs - prefers PTNS  
S. Charalampous, Limassol (CY) |
| 11:45 - 12:00 | Associated abstract presentations |
| 125 | **In females with overactive bladder, an alternative injection paradigm for onabotulinumtoxinA is associated with low clean intermittent catheterisation use**  
By: Macdiarmid S. 1, Glazier D. 2, Shapiro A. 3, McCammon K. 4, McCrery R. 5, Jarnagin B. 6, Boroujerdi A. 7, Bai Z. 8, Gao G. 9, Patel A. 10  
1Alliance Urology Specialists, Dept. of Urology, Greensboro, United States of America,  
2Virginia Urology, Dept. of Urology, Emporia, United States of America,  
3Chesapeake Urology, Dept. of Urology, Owings Mills, United States of America,  
4Eastern Virginia Medical School, Dept. of Urology, Virginia Beach, United States of America,  
5Adult Pediatric Urology, Dept. of Urology, Omaha, United States of America,  
6Center for Pelvic Health, Female Pelvic Medicine & Reconstructive Surgery, Franklin, United States of America,  
7Allergan plc, Dept. of Urology, Irvine, United States of America,  
8Allergan plc, Biostatistics, Madison, United States of America,  
9Allergan plc, Medical Safety, Madison, United States of America,  
10Allergan plc, Medical Affairs (Neurology and Urology), Marlow, United Kingdom |
| PT235 | **Exploration of litoxetine (LTX): A potential novel treatment for mixed urinary incontinence (MUI)**  
By: Haab F.  
Hopital Tenon, Dept. of Urology, Paris, France |